DYRK1A Inhibition Results in MYC and ERK Activation Rendering KMT2A-R Acute Lymphoblastic Leukemia Cells Sensitive to BCL2 Inhibition

The authors observed that pharmacologic dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibition markedly reduced human KMT2A-rearranged B-acute lymphoblastic leukemia cell proliferation in vitro and potently decreased leukemia proliferation in vivo in drug-treated patient-derived xenograft mouse models.